Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,305 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab.
Zhang W, Gordon M, Schultheis AM, Yang DY, Nagashima F, Azuma M, Chang HM, Borucka E, Lurje G, Sherrod AE, Iqbal S, Groshen S, Lenz HJ. Zhang W, et al. Among authors: gordon m. J Clin Oncol. 2007 Aug 20;25(24):3712-8. doi: 10.1200/JCO.2006.08.8021. J Clin Oncol. 2007. PMID: 17704420 Clinical Trial.
Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data.
Margolin K, Gordon MS, Holmgren E, Gaudreault J, Novotny W, Fyfe G, Adelman D, Stalter S, Breed J. Margolin K, et al. Among authors: gordon ms. J Clin Oncol. 2001 Feb 1;19(3):851-6. doi: 10.1200/JCO.2001.19.3.851. J Clin Oncol. 2001. PMID: 11157039 Clinical Trial.
Outpatient biochemotherapy with interleukin-2 and interferon alfa-2b in patients with metastatic malignant melanoma: results of two phase II cytokine working group trials.
Flaherty LE, Atkins M, Sosman J, Weiss G, Clark JI, Margolin K, Dutcher J, Gordon MS, Lotze M, Mier J, Sorokin P, Fisher RI, Appel C, Du W. Flaherty LE, et al. Among authors: gordon ms. J Clin Oncol. 2001 Jul 1;19(13):3194-202. doi: 10.1200/JCO.2001.19.13.3194. J Clin Oncol. 2001. PMID: 11432886 Clinical Trial.
Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma.
McDermott DF, Regan MM, Clark JI, Flaherty LE, Weiss GR, Logan TF, Kirkwood JM, Gordon MS, Sosman JA, Ernstoff MS, Tretter CP, Urba WJ, Smith JW, Margolin KA, Mier JW, Gollob JA, Dutcher JP, Atkins MB. McDermott DF, et al. Among authors: gordon ms. J Clin Oncol. 2005 Jan 1;23(1):133-41. doi: 10.1200/JCO.2005.03.206. J Clin Oncol. 2005. PMID: 15625368 Clinical Trial.
Molecular determinants of cetuximab efficacy.
Vallböhmer D, Zhang W, Gordon M, Yang DY, Yun J, Press OA, Rhodes KE, Sherrod AE, Iqbal S, Danenberg KD, Groshen S, Lenz HJ. Vallböhmer D, et al. Among authors: gordon m. J Clin Oncol. 2005 May 20;23(15):3536-44. doi: 10.1200/JCO.2005.09.100. J Clin Oncol. 2005. PMID: 15908664
Gene polymorphisms of epidermal growth factor receptor and its downstream effector, interleukin-8, predict oxaliplatin efficacy in patients with advanced colorectal cancer.
Zhang W, Stoehlmacher J, Park DJ, Yang D, Borchard E, Gil J, Tsao-Wei DD, Yun J, Gordon M, Press OA, Rhodes K, Groshen S, Lenz HJ. Zhang W, et al. Among authors: gordon m. Clin Colorectal Cancer. 2005 Jul;5(2):124-31. doi: 10.3816/ccc.2005.n.025. Clin Colorectal Cancer. 2005. PMID: 16098254
Cyclin D1 and epidermal growth factor polymorphisms associated with survival in patients with advanced colorectal cancer treated with Cetuximab.
Zhang W, Gordon M, Press OA, Rhodes K, Vallböhmer D, Yang DY, Park D, Fazzone W, Schultheis A, Sherrod AE, Iqbal S, Groshen S, Lenz HJ. Zhang W, et al. Among authors: gordon m. Pharmacogenet Genomics. 2006 Jul;16(7):475-83. doi: 10.1097/01.fpc.0000220562.67595.a5. Pharmacogenet Genomics. 2006. PMID: 16788380 Clinical Trial.
Molecular determinants of irinotecan efficacy.
Vallböhmer D, Iqbal S, Yang DY, Rhodes KE, Zhang W, Gordon M, Fazzone W, Schultheis AM, Sherrod AE, Danenberg KD, Lenz HJ. Vallböhmer D, et al. Among authors: gordon m. Int J Cancer. 2006 Nov 15;119(10):2435-42. doi: 10.1002/ijc.22129. Int J Cancer. 2006. PMID: 16894565
4,305 results